CO94 Tepotinib Compared With Chemoimmunotherapy in First-Line Non-Small Cell Lung Cancer (NSCLC): Matching Adjusted Indirect Comparison (MAIC) of VISION in MET Exon 14 (METex14) Skipping NSCLC and KEYNOTE-189 in Wild-type NSCLC
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.173
https://www.valueinhealthjournal.com/article/S1098-3015(22)02377-4/fulltext
Title :
CO94 Tepotinib Compared With Chemoimmunotherapy in First-Line Non-Small Cell Lung Cancer (NSCLC): Matching Adjusted Indirect Comparison (MAIC) of VISION in MET Exon 14 (METex14) Skipping NSCLC and KEYNOTE-189 in Wild-type NSCLC
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02377-4&doi=10.1016/j.jval.2022.09.173
First page :
Section Title :
Open access? :
No
Section Order :
11334